通过ATF4-CHOP轴通过形式素A选择性杀死抵抗割的前列腺癌细胞
Tomoki Takei1,2, Yuki Hamamura1, Hiroshi Hongo3
1Department of Biosciences and Informatics, Faculty of Science and Technology, Keio University, Yokohama, Japan.
Cancer science
|September 27, 2024
概括
甲基素A通过触发亡,有效地杀死抵抗割的前列腺癌 (CRPC) 细胞. 这种新型化合物还在体内表现出显著的抗瘤作用,为CRPC治疗提供了一个有前途的新疗法途径.
科学领域:
- 在瘤学瘤学.
- 癌症治疗方法 癌症治疗方法
- 分子生物学分子生物学
背景情况:
- 前列腺癌最初依赖于雄激素,但经常发展为割抵抗性前列腺癌 (CRPC).
- 现有的CRPC疗法效果有限,需要开发新的治疗策略.
研究的目的:
- 为割耐性前列腺癌 (CRPC) 鉴定新型治疗剂.
- 在CRPC模型中研究形式素A的疗效和作用机制.
主要方法:
- 进行了药物选,使用已建立的侵略性CRPC细胞模型.
- 评估了形式素A对CRPC细胞活力和亡的影响.
- 在CRPC异种移植模型中评估形式素A的体内抗瘤活性.
主要成果:
- 在CRPC模型细胞中选择性诱导细胞死亡,节省父母前列腺癌细胞.
- 甲基素A通过内质网膜应激上调死亡受体5,激活CRPC细胞中的外部亡途径.
- 福米辛A在割裸体小鼠中表现出显著的体内抗瘤功效,对CRPC异种移植有显著的抗瘤功效.
结论:
- 福米辛A通过诱导亡,表现出强大的抗CRPC活性.
- 福米辛A代表了一种潜在的新型治疗剂,用于治疗抵抗割的前列腺癌.
相关概念视频
02:57Targeted Cancer Therapies
7.5K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.5K
02:56Treatment Resistant Cancers
3.3K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.3K